Literature DB >> 34919455

Contributions of endothelin-1 and l-arginine to blunted cutaneous microvascular function in young, black women.

John D Akins1, Rauchelle E Richey1,2, Jeremiah C Campbell1, Zachary T Martin1, Guillermo Olvera1,3, R Matthew Brothers1.   

Abstract

Non-Hispanic black (BL) individuals have the greatest prevalence of cardiovascular disease (CVD), relative to other racial/ethnic groups (e.g., non-Hispanic white population; WH), which may be secondary to blunted vascular function. Although women typically present with reduced CVD relative to men of the same racial/ethnic group, the prevalence is similar between BL women and men though the mechanisms differ. This study hypothesized that reduced microvascular function in young, BL women is associated with endothelin-1 (ET-1) overactivity or insufficient l-arginine bioavailability. Nine BL and nine WH women participated (age: 20 ± 2 vs. 22 ± 2 yr). Cutaneous microvascular function was assessed during 39°C local heating, whereas lactated Ringer's (control), BQ-123 (ET-1 receptor type A antagonist), BQ-788 (ET-1 receptor type B antagonist), or l-arginine were infused via intradermal microdialysis to modify cutaneous vascular conductance (CVC). Subsequent infusion of Nω-nitro-l-arginine methyl ester allowed for quantification of the nitric oxide (NO) contribution to vasodilation, whereas combined sodium nitroprusside and 43°C heating allowed for normalization to maximal CVC (%CVCmax). BL women had blunted %CVCmax and NO contribution to dilation during the 39°C plateau (P < 0.027 for both). BQ-123 improved this response through augmented NO-mediated dilation (P < 0.048 for both). BQ-788 and l-arginine did not alter the CVC responses (P > 0.835 for both) or the NO contribution (P > 0.371 for both). Cutaneous microvascular function is reduced in BL women, and ET-1 receptor type A may contribute to this reduced function. Further research is needed to better characterize these mechanisms in young, BL women.NEW & NOTEWORTHY Cardiovascular disease remains a burden in the United States non-Hispanic black (BL) population, although its manifestation through blunted vasodilation in this population is different between men and women. Accordingly, this study determined that reduced microvascular function in young, BL women may be partially controlled by endothelin-1 (ET-1) type A receptors, although neither type B receptors nor insufficient l-arginine bioavailability seems to contribute to this response. Accordingly, further research is needed to better characterize these ET-1 related mechanisms and illuminate other pathways that may contribute to this disparate vascular function in young, BL women.

Entities:  

Keywords:  cardiovascular disease; endothelin-1; l-arginine; non-Hispanic black women; vascular function

Mesh:

Substances:

Year:  2021        PMID: 34919455      PMCID: PMC8759956          DOI: 10.1152/ajpheart.00457.2021

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  59 in total

Review 1.  The human cutaneous circulation as a model of generalized microvascular function.

Authors:  Lacy A Holowatz; Caitlin S Thompson-Torgerson; W Larry Kenney
Journal:  J Appl Physiol (1985)       Date:  2007-10-11

2.  New approach to measure cutaneous microvascular function: an improved test of NO-mediated vasodilation by thermal hyperemia.

Authors:  Patricia J Choi; Vienna E Brunt; Naoto Fujii; Christopher T Minson
Journal:  J Appl Physiol (1985)       Date:  2014-06-05

3.  Alterations in endothelin type B receptor contribute to microvascular dysfunction in women who have had preeclampsia.

Authors:  Anna E Stanhewicz; Sandeep Jandu; Lakshmi Santhanam; Lacy M Alexander
Journal:  Clin Sci (Lond)       Date:  2017-11-23       Impact factor: 6.124

4.  The presence of African American race predicts improvement in coronary endothelial function after supplementary L-arginine.

Authors:  Jan L Houghton; Edward F Philbin; David S Strogatz; Mikhail T Torosoff; Steven A Fein; Patricia A Kuhner; Vivienne E Smith; Albert A Carr
Journal:  J Am Coll Cardiol       Date:  2002-04-17       Impact factor: 24.094

5.  Asymmetric dimethylarginine and reduced nitric oxide bioavailability in young Black African men.

Authors:  Narbeh Melikian; Stephen B Wheatcroft; Okechukwu S Ogah; Cliona Murphy; Phillip J Chowienczyk; Anthony S Wierzbicki; Thomas A B Sanders; Benyu Jiang; Edward R Duncan; Ajay M Shah; Mark T Kearney
Journal:  Hypertension       Date:  2007-01-29       Impact factor: 10.190

6.  L-Arginine supplementation or arginase inhibition augments reflex cutaneous vasodilatation in aged human skin.

Authors:  Lacy A Holowatz; Caitlin S Thompson; W Larry Kenney
Journal:  J Physiol       Date:  2006-05-04       Impact factor: 5.182

Review 7.  Amino acids, arginase and nitric oxide in vascular health.

Authors:  Ngan Ngoc Huynh; Jaye Chin-Dusting
Journal:  Clin Exp Pharmacol Physiol       Date:  2006 Jan-Feb       Impact factor: 2.557

8.  Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells.

Authors:  U Förstermann; J S Pollock; H H Schmidt; M Heller; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

9.  Reduced endothelium-dependent and -independent dilation of conductance arteries in African Americans.

Authors:  Umberto Campia; Wassim K Choucair; Melissa B Bryant; Myron A Waclawiw; Carmine Cardillo; Julio A Panza
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

10.  Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension.

Authors:  S Ergul; D C Parish; D Puett; A Ergul
Journal:  Hypertension       Date:  1996-10       Impact factor: 10.190

View more
  1 in total

Review 1.  Assessments of microvascular function in organ systems.

Authors:  Cynthia Xu; Frank W Sellke; M Ruhul Abid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-03-25       Impact factor: 5.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.